Key Updates in Non–Small Cell Lung Cancer Emerging From WCLC 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss treatment and sequencing considerations in advanced non–small cell lung cancer.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the impact of the FDA approval of cemiplimab plus chemotherapy in advanced NSCLC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the management of immune-related adverse effects in advanced NSCLC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss 5-year data for cemiplimab plus chemotherapy in advanced NSCLC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the use of immunotherapy after prior immunotherapy for early-stage NSCLC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss key data from the 2025 World Conference on Lung Cancer.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss future areas of research and unmet needs in non–small cell lung cancer.